Literature DB >> 30297065

Temporary Circulatory Support and Extracorporeal Membrane Oxygenation.

Kimber Eleuteri1, Michael Mathias Koerner2, Douglas Horstmanshof3, Aly El Banayosy3.   

Abstract

Cardiogenic shock (CS) refractory to conventional therapies continues to be a challenging medical syndrome, with poor prognosis and high complication and mortality rates. The application and use of temporary mechanical circulatory support (MCS) is a component in the treatment of CS patients and should be applied early in the presentation. Crucial to the success of their application, temporary MCS devices should be chosen based on degree of patient acuity and etiology of CS. Not all temporary MCS devices deliver the same degree of hemodynamic support and range from minimal support to systemic support via veno-arterial extracorporeal membrane oxygenation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute on chronic heart failure; Cardiogenic shock; Decompensated heart failure; ECMO; Temporary mechanical circulatory support; V-A ECMO

Mesh:

Year:  2018        PMID: 30297065     DOI: 10.1016/j.ccl.2018.06.002

Source DB:  PubMed          Journal:  Cardiol Clin        ISSN: 0733-8651            Impact factor:   2.213


  3 in total

1.  Venovenous Extracorporeal Membrane Oxygenation Combined with Fiberoptic Bronchoscopy-Assisted CO2 Cryotherapy in the Treatment of Massive Hemoptysis in Pregnancy: A Case Report.

Authors:  Ting Chen; Li Yao; Chunyan Zhu
Journal:  Int J Gen Med       Date:  2020-11-27

2.  Successful treatment of cardiac arrest following hysteroscopic surgery using extracorporeal membrane oxygenation: A case report.

Authors:  Ting Chen; Li Yao; Fei Tong; Chunyan Zhu
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

3.  Extracorporeal membrane oxygenation with continuous renal replacement therapy to treat metformin-associated lactic acidosis: A case report.

Authors:  Ting Chen; Chunyan Zhu; Bao Liu
Journal:  Medicine (Baltimore)       Date:  2020-06-26       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.